Lilly Ventures has its roots in the scientific tradition of Eli Lilly and Company. Our investment philosophy drives us to seek great companies with compelling life science innovations.
Our collaborative partnership leverages the collective experience, deep expertise, and networks of our investment professionals for the benefit of our portfolio companies.
Aileron Therapeutics, Inc. announced the appointment of Hubert C. Chen, M.D., to Vice President of Clinical Development, Endocrine and Metabolic Disease.
FORMA Therapeutics announced the appointment of Rob Sarisky, Ph.D. to Chief Business Officer. Dr. Sarisky most recently served as Vice President of Oncology Business Development and Licensing at Janssen Pharmaceuticals.
InnoCentive, Inc. announced a collaboration with AARP Foundation, AARP's charitable affiliate, to help advance the Foundation's cause of improving the lives of millions of older Americans who struggle to meet their basic needs for nutritious food, safe and affordable housing, adequate income, and personal connections.
Cerulean Pharma Inc. announced that the first patient has been dosed in a Phase 2 study of its lead candidate, CRLX101, in platinum-resistant ovarian cancer patients.
Receptos Inc. announced the co-publication, with The Scripps Research Institute, of high resolution G-protein coupled receptor (GPCR) crystal structures in Science. This will enable rational drug discovery and design of GPCRs.
Cylene Pharmaceuticals established that RNA Polymerase I (Pol I) activity is essential for cancer cell survival. The findings published in Cancer Cell, show that Cylene’s Pol I inhibitor, CX-5461, selectively destroys cancer cells.
Cerulean Pharma Inc. announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC) patients.
Cerulean Pharma Inc. announced the first patient has been dosed in a Phase 1b/2a study of its lead product candidate, CRLX101, in combination with Avastin, in metastatic renal cell carcinoma (mRCC) patients.
FORMA Therapeutics and TGen Drug Development (TD2) announced an agreement to jointly develop transformative cancer therapies, leveraging the synergistic capabilities of both organizations.
Viamet Pharmaceuticals, Inc. announced that it has entered into a Non-Clinical Evaluation Agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Under this agreement, Viamet will utilize NIAID’s preclinical services program to develop broad-spectrum antifungal agents.
Protagonist entered into a collaboration agreement with Zealand Pharma to identify novel peptide drug candidates by utilizing Zealand Pharma’s expertise in peptide optimization technology.
Sutro Biopharma announced the closing of the $16.5 million second tranche of its Series C financing. This funding will be utilized to develop next generation antibody drug conjugates and bi-specific antibody platforms.
HemaQuest Pharmaceuticals, Inc. announced that it closed a $13 million extension of their Series B financing. This financing will enable a Phase 2b clinical study of HQK-1001 in patients with sickle cell disease.
Viamet Pharmaceuticals, Inc. announced the appointment of Richard D. Katz, M.D. to the newly created position of Chief Business and Financial Officer. Dr. Katz will be responsible for strategic planning and direction, overseeing commercial and financial operations and execution of the company’s corporate and business development activities.
Zalicus Inc. and Hydra Biosciences, Inc. announced that they have entered into a collaboration to advance development of Zalicus’ preclinical ion channel modulator product candidates for the treatment of pain.
InnoCentive, Inc. announced its acquisition of UK-based OmniCompete Limited. OmniCompete, well known for its annual Global Security Challenge, has executed nearly two dozen high-profile Challenges in the areas of security, energy, healthcare, and cloud computing.
Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the appointment of Chris Guiffre as Senior Vice President and Chief Business Officer, a newly created position.
FORMA Therapeutics today announced an exclusive alliance with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies, in which the two companies will collaborate on the discovery, development and commercialization of novel small molecule drug candidates that target tumor metabolism mechanisms.
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) and Hydra Biosciences, Inc. today announced plans to begin a Phase 1 clinical trial for a small molecule antagonist of the human Transient Receptor Potential Ankyrin repeat 1 (TRPA1) ion channel discovered in a collaboration between Cubist and Hydra.
Sutro Biopharma appointed James A. Wells, Ph.D., who has a depth of expertise and defining experience in protein engineering, and James R. Swartz, Sc.D., a leading expert in the field of cell-free protein synthesis, to the Sutro Scientific Advisory Board. Dr. Wells will serve as Chairman of the SAB
FORMA Therapeutics announced a research and development collaboration with Boehringer Ingelheim to discover and develop novel drug candidates for the treatment of cancer.
Viamet Pharmaceuticals, Inc., announced that dosing has begun in a Phase 1/2 clinical trial of VT-464, an oral, potent and lyase-selective CYP17 inhibitor for the treatment of castration-refractory prostate cancer (CRPC). VT-464 is a novel, non-steroidal, small molecule discovered by Viamet Pharmaceuticals using its proprietary Metallophile® Technology.
Receptos Inc. announced the establishment of a collaboration with Ono Pharmaceutical Co., Ltd. (Osaka, Japan) for the research and development of small molecule modulators of an undisclosed G–protein coupled receptor (GPCR) target. Under the terms of the agreement, Receptos will use its proprietary technology platform to produce high resolution protein crystal structures of the discovery target and drive Ono’s structure–based drug design efforts.
Aileron Therapeutics, Inc. announced the expansion of an existing drug discovery collaboration with Roche adding a third target in inflammatory disease to the existing oncology targets.
Cerulean Pharma presented final data from the non-small cell lung cancer Phase 1/2a clinical study of CRLX101 at the AACR-NCI-EORTC conference. The drug was well tolerated at the maximum tolerated dose (MTD) and provided encouraging progression free survival (PFS) times.
Viamet Pharmaceuticals Appoints Former Novartis Executive Marc Rudoltz, M.D. as Chief Medical Officer.
GlobeImmune and Gilead Announce Hepatitis B License and Collaboration Agreement.
Viamet Pharmaceuticals Initiates Phase 1 Clinical Trials for Best-in-Class Novel Antifungal VT-1161.
HemaQuest Pharmaceuticals, Inc., completed enrollment of a 52-patient randomized, multi-dose Phase 2 study in patients with sickle cell disease, designed to evaluate the safety and tolerability of HQK-1001.
FORMA Therapeutics was named by FierceBiotech as one of the 2011 Fierce 15, designating it as one of the most promising private biotechnology companies in the industry.
Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, announced that FierceBiotech has named the Company one of 2011's Fierce 15 companies, designating it as one of the most promising private biotechnology companies in the industry.
Viamet anti-fungal program was selected for inclusion by the National Institutes of Health program for Therapeutics for Rare and Neglected Diseases (TRND) Program.
Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.
Sheila Gujrathi, M.D., joins Receptos as Chief Medical Officer from Bristol-Meyers Squibb.
Nimbus Discovery LLC, a biopharmaceutical company using state-of-the-art computational technology to discover novel medicines against exciting but previously inaccessible disease targets, today announced the close of a $24MM Series A financing. The investment was co-led by Atlas Venture, Lilly Ventures, and SR One.
FORMA Therapeutics announced today that it entered into an agreement granting Genentech, a member of the Roche Group, exclusive worldwide rights to acquire a pre-clinical small molecule program against a single undisclosed cancer target.
GlobeImmune announces safety and immunogenicity data from clinical trials in lung cancer with KRAS mutations and CEA expressing cancers.
Sutro Biopharma, which is developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, announced that a study published in the July issue of Biotechnology and Bioengineering demonstrates that the company’s biochemical protein synthesis technology platform enables fast and high-yield protein synthesis, scale-up, and straightforward purification by producing a fully bioactive, human, cytokine at titers of 700 mg/L in only 10 hours.
Cerulean Pharma Inc. appoints Edward Garmey, M.D. to serve as Chief Medical Officer and Senior Vice President.
Aileron hires industry veteran Anthony Manning, Ph.D. as Senior Vice President of Research and Preclinical Development.
Cerulean presents Phase 2a interim clinical data that highlight observations of stable disease in advanced non-small cell lung carcinoma (NSCLC) patients.
Receptos, Inc., announced today that their highly selective sphingosine-1-phosphate receptor 1 (S1P1) agonist, RPC1063, has been administered to the first subject in a single-ascending and multiple-ascending dose design Phase 1 clinical safety study.
Andrew von Eschenbach, M.D., Former FDA Commissioner and Leading Prostate Cancer Expert, Elected to Viamet Pharmaceuticals Board of Directors.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Protagonist Therapeutics, Inc. announced that they have entered into a collaboration to discover novel peptides for potential development by Ironwood. The collaboration capitalizes on Protagonist's proprietary disulfide rich peptide (DRP) technology platform, and provides Ironwood with the opportunity to develop novel peptides and treatments against clinically–validated targets in therapeutic areas with significant unmet medical needs.
Sutro Biopharma enters into a multiyear collaboration with Pfizer for the research, development and commercialization of novel peptide-based therapeutics.
Receptos announced an exclusive collaboration focused on structure determination and lead generation for a high value G-protein Coupled Receptor (GPCR) target.
Avid acquisition closes.
Sutro Biopharma today announced that it has appointed Trevor Hallam, Ph.D., as Chief Scientific Officer (CSO). Dr. Hallam will lead Sutro's ongoing efforts in the application of the company's proprietary protein biochemical synthesis platform for the research and development of novel and biosuperior therapeutics.
Industry veteran will strengthen Receptos’s clinical and commercial expertise in multiple sclerosis and expand activities including the potential to acquire additional focused therapeutic assets.
Eisai and FORMA Therapeutics announced a strategic drug discovery collaboration. Eisai will have non-exclusive access to FORMA's Diversity Oriented Synthesis (DOS) chemistry-generated compound library and cell-based screening platforms to support the discovery of novel compounds for Eisai's pipeline and an option for technology transfer of FORMA's cell-based screening platform.
Cylene Pharmaceuticals presents advances in the development of their first-in-class CK2 inhibitor, CX-4945, at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Targets.
GlobeImmune Announces HCV End of Treatment Response in Phase 2b
Roche enters $1.1B deal with Aileron on up to five undisclosed targets in oncology, virology, inflammation, metabolism and central nervous system.
Gilead Science and CGI announce the signing of a Definitive Agreement whereby Gilead will acquire CGI.
Announced today that William Moore, Ph.D. has joined the company as Chief Scientific Officer.
Silence Therapeutics plc (“the Company”) (AIM: SLN) and Intradigm Corporation announce that the companies have completed their merger to form a leading company in the field of RNAi (RNA interference).
Copyright © 2013 Lilly Ventures Management Company, LLC. All rights reserved.